...
机译:Brentuximab Vedotin用于治疗自体干细胞移植后复发或难治性霍奇金淋巴瘤的患者
King Fahad Specialist HospitalDammam Saudi Arabia;
Prince of Wales Hospital and University of NSWRandwick NSW Australia;
Takeda PharmaceuticalsSydney NSW Australia;
Takeda Europe &
Canada Business Unit (EUCAN)Zurich Switzerland;
SYNEVi Pty LimitedChatswood NSW Australia;
Health Economics and Outcomes Research LtdCardiff UK;
Health Economics and Outcomes Research LtdCardiff UK;
Takeda Europe &
Canada Business Unit (EUCAN)Zurich Switzerland;
BC Cancer Centre for Lymphoid Cancer and the University of British ColumbiaVancouver BC Canada;
Hodgkin lymphoma; recurrence; autologous stem cell transplant; brentuximab vedotin; survival analysis;
机译:Brentuximab Vedotin加ESHAP(BRESHAP)是一种有效的组合,可在自体干细胞移植之前诱导难治性和复发性霍奇金淋巴瘤患者的缓解:西班牙淋巴瘤和骨髓移植(GELTAMO)试验
机译:Pembrolizumab单药治疗初级耐火经典霍奇金淋巴瘤淋巴瘤,后者复制后复制后爆发性干细胞移植和/或Brentuximab Vedotin治疗:Keynote-087亚组分析
机译:Brentuximab Vedotin与医生选择化疗的现实世界效力,在英国和德国自体干细胞移植后复发/难治性Hodgkin淋巴瘤患者
机译:用于治疗犬淋巴瘤的自体外周血干细胞移植
机译:与进行自体外周血干细胞移植的淋巴瘤患者疲劳相关。
机译:二线brentuximab vedotin在复发或难治性霍奇金淋巴瘤中的自体干细胞移植
机译:PSY5比较自体干细胞移植(ASCT)后复发/难治性霍奇金淋巴瘤(HL)患者的布伦妥昔单抗维多汀总生存数据与护理标准